Genetic disruption of the bradykinin receptors B1 (BDKRB1) and B2 (BDKRB2) decreases inflammatory sensitivity in a variety of disease‐specific models, including the multiple sclerosis model experimental autoimmune encephalomyelitides and a gout model induced by monosodium urate injection (Dutra et al., 2013; Silva et al., 2016). Here, BDKRB2 is linked to multiple sclerosis.